Late gadolinium enhancement was significantly associated with poor outcomes in patients with peripartum cardiomyopathy (HR 1.34; 95% CI 1.04-1.73; p=0.02).
Meta-Analysis (n=227)
Does the presence of late gadolinium enhancement predict poor outcomes in patients with peripartum cardiomyopathy?
Late gadolinium enhancement is associated with poor clinical outcomes in peripartum cardiomyopathy and may provide complementary prognostic value for risk stratification.
Hazard Ratio: 1.34 (95% CI 1.04–1.73)
p-value: p=0.02
Background Peripartum cardiomyopathy (PPCM) is a rare but life-threatening condition occurring during late pregnancy or the postpartum period. Although late gadolinium enhancement (LGE) has prognostic value in other cardiomyopathies, its role in PPCM remains unclear. This study aimed to evaluate the prognostic significance of LGE in PPCM.Methods Three electronic databases were systematically searched to identify studies assessing the association between LGE and clinical outcomes in PPCM. Outcomes included reduced left ventricular ejection fraction (LVEF), arrhythmia, heart failure decompensation, device implantation, transplantation, and mortality. Pooled hazard ratios were calculated using the generic inverse variance method.Results Eight cohort studies involving 227 patients were included. The mean age was 32.2 ± 6.6 years and mean LVEF was 30.5%. The pooled hazard ratio analysis revealed that LGE was significantly associated with poor outcomes (HR 1.34, CI 1.04–1.73 I2 = 52%, p = 0.02). Further analysis demonstrated that LGE was strongly linked to adverse clinical outcomes (HR 2.95, CI 1.62–5.37, I2 = 0%, p = 0.004), whereas no significant association was observed with persistently reduced LVEF (HR 1.11, CI 0.85–1.45, I2 = 14%, p = 0.45).Conclusion LGE is associated with poor outcomes in PPCM and may provide complementary prognostic value for risk stratification.Protocol registration www.crd.york.ac.uk/prospero identifier is CRD42024568502.
Nurhafizah et al. (Fri,) conducted a meta-analysis in Peripartum cardiomyopathy (n=227). Late gadolinium enhancement was evaluated on Poor outcomes (HR 1.34, 95% CI 1.04-1.73, p=0.02). Late gadolinium enhancement was significantly associated with poor outcomes in patients with peripartum cardiomyopathy (HR 1.34; 95% CI 1.04-1.73; p=0.02).